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Abstract: Two new analogues of alstoscholarisine A, containing a phenyl or butyl 
substituent at the C-19 position, have been prepared in racemic form from the 
known skatole derivative. The syntheses of these compounds were accomplished in 
13 steps, with a late-stage formation of the C-19 stereocenter. These derivatives are 
expected to have significantly changed biological activity, compared to alstoschol-
arisine A – a potent neuroactive natural product. 
Keywords: аlkaloids; neuronal stem cells; Alstonia scholaris. 
INTRODUCTION 
Over last decades, as medicine made substantial progress towards a better 
understanding of neurological disorders, neuroactive substances have emerged as 
a very interesting and challenging area of research for chemists. Among these 
substances, especially enthralling targets are those that could modulate the proli-
feration and differentiation of neuronal stem cells (NSC).1–5 The use of small 
molecules to affect NSC and prevent a loss of neuronal activity is very attractive 
and promising from a therapeutic point of view; during the last few years, several 
such compounds were identified.6–10  
Recently, five monoterpenoid indole alkaloids, alstoscholarisine A–E (1–5), 
were isolated from the leaves of Alstonia scholaris (Fig. 1).10 Although all these 
compounds show noteworthy ability to enhance adult NSC proliferation, the 
most potent one, alstoscholarisine A (1), has attracted significant attention among 
synthetic organic chemists. This interest was provoked partially by its exciting 
bioactivity, but also by its complex molecular structure, with 6/5/6/6/6-fused 
bridge rings and five contiguous chiral centers. As a result, very elegant syn-
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theses of this intriguing molecule have been published so far, two racemic and 
two enantioselective syntheses.11–14 
 
Fig. 1. Structures of alstoscholarisine A–E (1–5). 
However, neither of these synthetic efforts was oriented toward the synthesis 
of alstoscholarisine A analogues. The fact that the only structural difference 
between alstoscholarisine A (1) and alstoscholarisine E (5) (which exhibits 
slightly lower activity) is the absolute configuration of the carbon C-19, indicates 
that a substituent at C-19 might be important for the bioactivity. 
We have published a racemic synthesis of alstoscholarisine A (1) in 2016, in 
which the stereocenter at C-19 was formed in the last steps of the synthesis.11 
Therefore, it was decided to modify these last steps and to synthesize compounds 
6 and 7, two new C-19 analogues of alstoscholarisine A (Scheme 1), in order to 
test whether a nonpolar, longer alkyl or an aryl substituent could alter the bioact-
ivity. These two analogs could be accessible from the common lactonic inter-
mediate 8 by the addition of the corresponding alkyl- or aryl-lithium reagent, fol-
lowed by a subsequent stereoselective reduction of the intermediary hemiketal. 
Scheme 1. Structure of lactone 8 and novel 




All chromatographic separations were performed on silica gel, 10–18 mesh, 60 Å (dry 
flash) and Silica 60 (0.063–0.200 mm), Merck. Standard techniques were used for the purific-
ation of the reagents and solvents. Petroleum ether refers to the fraction boiling at 70–72 °C. 
NMR spectra were recorded with a Bruker Avance III 500 (1H-NMR at 500 MHz, 13C-NMR 
at 125 MHz). Chemical shifts are expressed in ppm (δ) using tetramethylsilane as the internal 
standard, coupling constants (J) are in Hz. IR spectra were recorded with a Nicolet 6700 FT 
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instrument and expressed in cm-1. Mass spectra were obtained with an Agilent Technologies 
6210 TOF LC–MS instrument (LC: series 1200). 
Compound 21. PhLi (1.9 M in dibutyl ether; 60 μL; 0.114 mmol; 3.4 eq) was added to a 
cold (–78 °C) solution of lactone 8 (10 mg; 0.033 mmol) in dry tetrahydrofuran (1.5 mL), 
under argon. After stirring for 15 min, the reaction mixture was diluted with ether, washed 
with brine and dried over anhydrous MgSO4. The solvent was removed on a rotovap and the 
residue was purified by column chromatography (CH2Cl2/MeOH=95:5), to afford 8.0 mg (63 
%) of the hemiketal 21, as a colorless film.  
Compound 22. n-BuLi (1.6 M in hexanes; 60 μL; 0.094 mmol; 3 eq) was added to a cold 
(–78 °C) solution of lactone 8 (9.3 mg; 0.031 mmol) in dry tetrahydrofuran (1.5 mL), under 
argon. After stirring for 15 min, the reaction mixture was diluted with ether, washed with 
brine and dried over anhydrous MgSO4. The solvent was removed on a rotovap and the resi-
due was purified by column chromatography (EtOAc/MeOH = 95:5), to afford 5.4 mg (49 %) 
of the hemiketal 22, as a colorless film.  
Compound 6. Triethylsilane (12 μL; 0.070 mmol; 3.5 eq) and trimethylsilyl trifluoro-
methanesulfonate (9 μL; 0.050 mmol; 2.5 eq) were added to a cold (–78 °C) solution of hemi-
ketal 21 (7.2 mg; 0.020 mmol) in dry dichloromethane (1.4 mL), under argon. The mixture 
was stirred at –78 °C for 45 min before the reaction was quenched by the addition of 3 drops 
of triethylamine. The reaction mixture was diluted with ether, washed with saturated sodium 
bicarbonate and brine, dried over anhydrous MgSO4 and evaporated to dryness. The crude 
product was purified by column chromatography (CH2Cl2/MeOH = 95:5), to afford 5.6 mg 
(66 %) of compound 6, as a colorless film.  
Compound 7. Triethylsilane (14 μL; 0.084 mmol; 3.5 eq) and trimethylsilyl trifluoro-
methanesulfonate (11 μL; 0.060 mmol; 2.5 eq) were added to a cold (–78 °C) solution of 
hemiketal 22 (8.9 mg; 0.023 mmol) in dry dichloromethane (0.7 mL) under argon. The 
mixture was stirred at –78 °C for 45 min before the reaction was quenched by the addition of 
3 drops of triethylamine. The reaction mixture was diluted with ether, washed with saturated 
sodium bicarbonate and brine, dried over anhydrous MgSO4 and evaporated to dryness. The 
crude product was purified by column chromatography (CH2Cl2/MeOH = 95:5), to afford 4.7 
mg (68 %) of compound 7 as a colorless film.  
The characterization data for the synthesized compounds are given in the Supplementary 
material to this paper. 
RESULTS AND DISCUSSION 
The synthesis of analogues 6 and 7 commenced with the aldol reaction of 
skatole derivative 911 and N-Alloc protected aldehyde 10,15 which was partially 
followed by the spontaneous migration of the Boc-group from nitrogen to the 
newly formed hydroxyl group (Scheme 2). Treatment of the reaction mixture 
with NaH ensured complete migration and subsequent in situ β-elimination of 
intermediate 11, to afford stereoselectively (E)-12. Palladium-catalyzed removal 
of the Alloc-protecting group delivered free amine 13, the intermediate for the 
key domino reaction that allowed the C and D rings of the target molecule to be 
constructed in one-step. Treatment of amine 13 with aldehyde 1416 triggered the 
sequence, followed by 6-exo-trig cyclization of the intermediary enamine and 
final intramolecular N,N-acetalization. Low diastereoselectivity was observed in 
the formation of the tetracyclic core and NOESY experiment showed that a mix-
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ture of C-16 epimers 15a and b was obtained in almost equimolar ratio (for the 
NOESY spectrum and correlations, see the literature data11). For this reason, we 
wished to improve further the yield of the desired isomer 15a. Simple treatment 
of the crude mixture of diastereoisomers 15a, b with DBU resulted in ester 
isomerization and the thermodynamically more stable tetracycle 15a was isolated 
in 71 % yield. Furthermore, the above-mentioned NOESY experiment also rev-
ealed the incorrect, i.e., axial, position of the selenium-containing substituent. 
Therefore, epimerization of the C-20 stereocenter prior the construction of tetra-
hydropyrane E-ring was necessary. Compound 15a was oxidized with mCPBA 
and thus the obtained selenoxide was treated with DIPA to afford alkene 16 in 
good yield. 
 
Scheme 2. Synthesis of tetracyclic intermediate 16. 
Reduction of ester group with DIBAL, followed by dihydroxylation of the 
double bond in 16 cleanly furnished triol 18 in almost quantitative yield, as an 
inseparable mixture of isomers (Scheme 3). Glycol cleavage in 18 was affected 
by treatment with lead tetraacetate to afford aldehyde 19, a substrate suitable for 
the C-20 epimerization. It is worth mentioning that aldehyde 19 was prone to 
decomposition, so it was subjected to isomerization directly, without purification. 
Initial experiments showed that axial position of the aldehyde group in 19 is 
thermodynamically favored: when the vinyl group in ester 16 was cleaved under 
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the described conditions, the obtained aldehyde underwent epimerization in the 
presence of DBU. However, the equilibrated mixture contained only 10–15 % of 
the desired equatorial isomer, thus indicating that the axial isomer is the thermo-
dynamically more stable one. The hypothesis was that the less stable equatorial 
isomer could be trapped instantly after epimerization by an intramolecular attack 
of the hydroxyl group to give the hemiacetal. Indeed, upon exposure to DBU in 
chloroform, axial aldehyde 19 was converted to a mixture of isomeric hemiace-
tals 20, which were immediately oxidized with DMP in a one-pot protocol to 
yield lactone 8. Finally, lactone 8 was treated with phenyllithium or n-butyl-
lithium, to afford the corresponding hemiketals 21 or 22, respectively. Addition 
of organolithium reagent to 8 was completely stereoselective, from the less 
crowded, convex face of the molecule. These hemiketals 21 and 22 were treated 
with TMSOTf and thus the formed oxonium ions were stereoselectively reduced 
with Et3SiH from the less hindered face to yield the alstoscholarisine A ana-
logues 6 and 7 in good yield.  
 
Scheme 3. E-ring formation and completion of the synthesis of 6 and 7. 
CONCLUSIONS 
To summarize, the first syntheses of the C-19 alstoscholarisine A analogues 
6 and 7 have been presented. These compounds were prepared in 13 steps, inc-
luding a late-stage incorporation of the C-19 substituent. As analogues 6 and 7 
were obtained in racemic forms, development of a HPLC method for the separ-
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ation of these enantiomers and subsequent evaluation of the biological activity of 
thus obtained optically pure compounds are currently underway. 
SUPPLEMENTARY MATERIAL 
Analytical and spectral data are available electronically at the pages of journal website: 
http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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И З В О Д  
СИНТЕЗА ДВА НОВА C-19 АНАЛОГА (±)-АЛСТОСХОЛАРИЗИНА А 
ФИЛИП БИХЕЛОВИЋ, ЗОРАНА ФЕРЈАНЧИЋ и ЗЛАТКО ЈОНЧЕВ 
Универзитет у Београду – Хемијски факултет, Студентски трг 12–16, 11158 Београд 
Два нова аналога алстосхоларизина А, који садрже фенил- или бутил-супституент у 
положају 19, синтетисана су у рацемском облику из познатог деривата скатола. Синтеза ових 
једињења остварена је у 13 корака, при чему се стереоцентар у положају 19 формира у 
последњим корацима синтезе. Очекује се да ће биолошке активности ових једињења бити 
различите од биолошке активности алстосхоларизина А – неуроактивног природног 
производа. 
(Примљено 12. фебруара, ревидирано 20. марта, прихваћено 25. марта 2019) 
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